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yang normal dan yang diberi diet lemak tinggi 
melalui  kenofrotolsikan
ABSTRAK
     Asid lemak bebas tepu (saturated free fatty acids, SAFFA) mengaruh kesan mudarat 
mereka melalui aruhan laluan inflamatori intrasel yang berkaitan dengan rintangan 
insulin.  Dalam  bidang bioperubatan, keadaan ini dikenali sebagai sindrom 
metabolisme. Gentamicin merupakan suatu antibiotik aminoglikosid yang digunakan 
dengan meluas.  Tindakan nefrotoksiknya dicirikan oleh tubul berlingkar proksimal dan 
kerosakan pada membran glomerular. Mekanisme kenefrotoksikan berkaitan rapat 
dengan stres oksidatif dan penjanaan radikal bebas.
      Dewasa ini ditemui bahawa ekstrak daun sawit mempunyai beberapa kepentingan 
bioperubatan kerana polifenol yang terkandung di dalamnya boleh bertindak balas bagi 
mengurangkan stres oksidatif.   
     Kajian kami bertujuan menentukan impak daripada menggantikan elemen diet 
penting dalam makanan yang diperkaya dengan SAFFA terhadap  kemajuan kerosakan 
ginjal dan kaitannya dengan perubahan hemodinamik dan metabolisme dalam model 
tikus yang kenefrotoksikan diaruh dengan gentamicin.  Kajian ini juga menilai kesan 
xxix
profilaktik dalam ekstrak daun sawit (palm oil leaf extract POLE) terhadap kemajuan 
gangguan ini.  
Ketidakfungsian ginjal dinilai melalui ukuran serum kreatinin, klearans kreatinin, 
pecahan dan kumuhan / eksresi mutlak daripada natrium dan kalium. Malonildialdehid 
(suatu biopenanda bagi stres oksidatif) dalam homogen ginjal dan kumuhan protein 
urin.  Keputusan menunjukkan bahawa terdapat insidens kenefrotoksikan yang amat 
tinggi dalam tikus yang diberi diet yang diperkaya dengan SAFFA dibandingkan 
dengan tikus yang diberi diet yang standard.  Kenefrotoksikan digred sebagai sedikit 
bagi kumpulan gagal-ginjal yang diberi diet yang standard.  Sebaliknya, digred sebagai 
sederhana hingga teruk, bagi yang diberi diet yang diperkaya dengan SAFFA. Dos 
POLE yang tinggi boleh membataskan  kemajuan kenefrotoksikan dan perkembangan 
stres oksidatif dalam tisu ginjal. Dari sudut lain, sindrom metabolisme dinilai melalui 
ujian tolerans oral-glukos (oral-glucose tolerance test, OGTT), ukuran profil lipid dan 
indeks obesiti / kegemukan. Kajian menunjukkan kemerosotan dalam sindrom 
metabolisme pada tikus yang diberi diet yang diperkaya dengan SAFFA. Pemberian 
gentamicin bersama diet ini menyebabkan kemerosotan yang amat sedikit dalam 
tolerans glukosa tanpa impak yang ketara  terhadap profil lipid. Sindrom metabolisme 
yang diaruh dengan SAFFA dikaitkan dengan perubahan kardiovaskular yang dicirikan 
oleh hipertensi dan kekakuan yang amat tinggi pada arteri. Selepas pemberian 
gentamicin bersama diet SAFFA, didapati tekanan semakin berkurangan dan kekakuan 
kekal.  Sebaliknya, injeksi gentamicin  pada tikus yang diberi diet standard, tidak 
menunjukkan sebarang perubahan kardiovaskular. Kemajuan sindrom metabolisme dan 
perubahan kardivaskular terbatas sedikit selepas pemberian  POLE.   
xxx
     Secara keseluruhan, sindrom metabolisme yang diaruh SAFFAs mempercepat 
kemajuan   kenefrotoksikan dalam mekanisme yang berkaitan untuk penjanaan radikal 
bebas yang tinggi.  POLE sebagai suatu produk makanan kesihatan menghasilkan kesan 
propilaktik yang amat sedikit terhadap impak ini.   . 
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Effect of palm oil (Elias guinensis) leaf 
standardized extract on progression of renal 
dysfunction and arterial stiffness in normal 
and high fat diet fed Sprague Dawley rats 
with induced nephrotoxicity.
ABSTRACT
       Saturated free fatty acids (SAFFAs) trigger their deleterious effects through 
inducing the intracellular inflammatory pathway related to insulin resistance. This 
results in a constellation of biomedical disorders known as metabolic syndrome. 
Gentamicin is a widely used aminoglycoside antibiotic. Its nephrotoxic action is 
characterized by both proximal convoluted tubules and glomerular membrane damage. 
The mechanism of nephrotoxicity is closely related to oxidative stress and free radicals 
generation. 
      It is found nowadays that palm oil leaf extract has got some biomedical importance 
due to its content of polyphenols which act to counteract the oxidative stress. 
     Our study aimed to find the impact of replacing the essential dietary elements in 
food by SAFFAs enriched fats on progression of renal damage and its associated 
hemodynamic and metabolic changes in rat's model of gentamicin induced 
xxxii
nephrotoxicity. The study also evaluated the prophylactic effect of palm oil leaf extract 
(POLE) on progression of these disorders. 
    Renal dysfunction was assessed through measuring serum creatinine, creatinine
clearance, fractional and absolute excretion of both sodium and potassium, 
malonyldialdehyde (a biomarker of oxidative stress) in renal homogenate and the 
urinary protein excretion. The results showed a higher incidence of nephrotoxicity in 
the rats fed with the diet enriched with SAFFAs as compared to those fed with the 
standard diet. The nephrotoxicity was graded as mild for the renal failure group fed with 
the standard diet and moderate to severe for those fed with the SAFFAs enriched diet. 
High dose of POLE could have limited the progression of nephrotoxicity and oxidative 
stress development in the renal tissue. Metabolic syndrome was assessed through 
performing oral-glucose tolerance test (OGTT), measuring the lipid profile and obesity 
indices. The study showed deterioration in metabolic syndrome after feeding the rats 
with the diet rich in SAFFAs. Gentamicin co-administration along with this diet 
deteriorated the glucose tolerance without producing a noticeable impact on lipid 
profile. The metabolic syndrome induced by the SAFFAs was associated with 
cardiovascular changes characterized by hypertension and higher arterial stiffness. The 
blood pressure was reduced after gentamicin co-administration along with the SAFFAs 
enriched diet while the stiffness remained comparable. Moreover, gentamicin injection 
to the rats fed with the standard diet did not produce any cardiovascular change. 
Progression of metabolic syndrome was limited after POLE co-administration. 
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     Overall, metabolic syndrome induced by SAFFAs hastens the progression of 
nephrotoxicity in a mechanism related to higher free radicals generation. POLE as a 
health product produced a prophylactic effect against these impacts.
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Chapter One 
Introduction 
 
1.1 Physiology of kidneys 
      Kidneys are bean shaped organs, located in the abdominal cavity. They have a 
contact with the diaphragm and the posterior abdominal muscles and are surrounded by 
both the 11th and 12th ribs. Both kidneys are surrounded by the epirenal adipose 
connective tissue and some visceral organs. (Kinne, 1989).  
 
1.1.1 General structure 
   Kidneys are oval shaped organs. They have two parallel borders; the concave border 
which is directed toward the body’s midline and the convex border which is directed 
laterally. There is a slit in the middle of the concave border called helium (the site 
where the kidney receives the renal artery and both the renal vein and ureter emerge 
(Lote, 2000).  
      Renal tissue is made up of two layers; cortex and medulla. It is surrounded by a 
layer of loose connective tissues, called renal capsule. The cortex appears as a red 
colored spotted area due to the presence of numerous capillary bundles that represent 
Malpighian corpuscles. The saggital section of the kidney shows the presence of 8-18 
pyramidal triangular areas whose bases are on the cortex and their apices are inside the 
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medulla. These areas are known as renal pyramids, they are marked by fine converging 
lines known as medullary rays which represent the collecting ducts. Renal pyramid 
apices are known as renal papillae where the urine that is formed in conducting tubules 
leave the pyramids through some small orifices into a space called the renal sinus. Then 
it drains to the renal pelvis and ureter (Kinne, 1989; Lot, 2000). 
 
 1.1.1.1 Nephrons 
     Nephrons are the basic functional units of renal tissue. There are about one million 
nephrons in each kidney. They are composed of the filtration unit that is known as the 
glomerulus and a tubular system; responsible for re-absorption and secretion of 
biochemical entities. Each renal glomerulus (Malpighian corpuscle) is made of a 
globular bundle of capillaries surrounded by a crescent shaped chamber (Bowman’s 
capsule). The glomerular capillary is made of separate loops of capillaries but it appears 
as a tangled mass of vessels. Bowman’s capsule is made up of a single layer of flat cells 
known as podocytes (Kinne, 1989; Sherwood, 2008).  
     The tubular system of nephron is made up of four distinct zones; proximal 
convoluted tubule (PCT), loop of Henle, distal convoluted tubule (DCT) and collecting 
tubule (CT) that deliver urine into the orifices present on renal papillae. Both PCT and 
DCT are the twisted and coiled portions located in the renal cortex. Loop of Henle & 
CT constitute the converging lines which mark the medullary renal pyramid (Sherwood, 
2008; Kinne, 1989).   
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Figure 1.1 a) Saggital structure of kidney, b) General structure of nephron c) Detailed 
outline of renal tubules. (Adapted from http://www.google.com.my/images 
?hl=en&q=kidney+structure+image).                                                
 
1.1.1.2 Renal glomeruli 
     Renal glomeruli are made up of a capillary bundle surrounded by a crescent shaped 
chamber, known as Bowman’s capsule. Blood enters the glomerular capillary tuft 
through the afferent arteriole and leaves it through the efferent arterioles. Along its 
passage through the capillary tuft, some of the plasma passes into the lumen of 
Bowman’s capsule through the glomerular membrane (Kinne, 1989; Sherwood, 2008).      
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      The glomerular membrane is made up of the wall of glomerular capillary loop and 
the alignment of epithelial cells called podocytes which constitute the wall of Bowman 
capsule. The glomerular membrane sieve is made of three filtration layers; the first is 
represented by the fenestrae distributed among the capillary endothelial cells. It is a 
coarse filter layer which retains high gram molecular weight (g.m.wt) proteins, fat 
globules and blood cells. Underneath the capillary endothelium, there is another 
filtration unit. It is represented by an alignment of negatively charged glycoprotein and 
glycolipid molecules. It hinders penetration of the negatively charged proteins across 
the glomerular membrane and permits penetration of molecules with radii exceeding 60 
°A. The third unit is represented by podocytes. Podocytes are irregularly shaped and 
possess a number of intermingled primary and secondary processions leaving slits of 
rectangular pores measuring 140 x 40 °A, providing the most physically restrictive filter 
(Ota, et al, 1980).  
 
1.1.1.3 Proximal convoluted tubules PCT 
     PCT is a joining segment between Bowman’s capsule and loop of Henle. It is lined 
by simple cuboidal epithelial cells which are uniform in all parts of the tubule with 
some ultra-structural differences. Their plasma membrane plays an important role in 
their function. The site of the membrane that faces the tubular lumen is called the apical 
membrane while the one which faces the interstitial fluid space is called the basolateral 
membrane. The apical membrane is covered by a border made of densely packed 
microvilli, called brush border which increases the surface area upon which re-
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absorption takes place while the basolateral one contains proteins related Na+-K+ pump 
(Kinne, 1989). Their cytoplasm is densely packed, acidophilic in nature due to plenitude 
of mitochondria. Under the light microscope there is no obvious discrete margin among 
cells except for lateral interdigitations near the apical membrane creating a tight 
junction between the neighboring cells and leaving a space (called the intercellular 
space) between them at the site of basolateral membrane (Moffat, 1975). Most of the 
biochemical entities cross the PCT wall into the interstitial space either by trans-cellular 
pathway (crossing both the apical and basolateral membranes) or by crossing the tight 
intercellular junction into the intercellular space and then to interstitial fluid (para-
cellular pathway) ( Neumann and Rector, 1979).  
     According to the gross appearance, PCT is divided into; pars convoluta & pars 
recta. Pars convoluta is the initial convoluted portion while recta are the straight 
descending second portion. PCT is subdivided also according to the functional 
difference into S1 and S2 segments or according to ultra structural difference into S1, 
S2 and S3 (Tisher and Osborn, 1969 ; Barrett and Heidger, 1975). 
  
1.1.1.4 Loop of Henle 
     It is the joining segment between PCT and DCT. It is made up of two parallel tubes 
penetrate deep into medulla where they connect in a hair pin like manner. It is 
surrounded by an anastomosis of capillary system called vasa recti renis. Both loop of 
Henle and vasa recta renis play an important role in countercurrent multiplication 
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mechanism that is responsible for water re-absorption from the collecting tubules 
(Moffat, 1975; Kinne, 1989).  
 
1.1.1.5 Distal convoluted tubules 
      It is the joining segment between loop of Henle and the collecting tubular system. It 
is lined by simple cuboidal epithelial cells, similar to that in PCT with some minor 
differences as paucity of brush border, making their lumen wider than that of PCT. 
Their cytoplasm is less acidic and less densely packed than that of PCT due to their 
lower content of mitochondria. DCT is responsible for re-absorption of some ions as 
chloride, sodium, potassium and calcium and fine adjustment of tubular fluid and PH. A 
part of DCT gets near the afferent arteriole; its epithelial cells are more tightly packed 
and specialized. It is called macula densa that is responsible for blood osmolality 
monitoring (Moffat, 1975; Kinne, 1989).  
 
1.1.1.6 Collecting tubules system  
     A series of tubules drain the nephronal tubular fluid from DCT into renal papilla.    
The lining epithelium of the CT system participates in electrolyte homeostasis through 
potassium ion secretion and sodium re-absorption, pH adjustment and the anti-diuretic 
hormone (ADH) mediated water re-absorption (Haas, et al., 1979). 
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1.1.2 Renal glomerular filtration and tubular function  
      Plasma free fluid transverses the three abovementioned sieving layers of the 
glomerulus into Bowman capsule. Rate of transfer is determined by Starling’s 
hypothesis which states that the filtration pressure of any capillary system is the 
algebraic sum of the opposing hydrostatic and oncotic pressures (Renkin and Robinson, 
1974).  
PUF= (PGC+∏ BC)-(PBC+∏ GC)  
 PUF, PGC, PBC, ∏ BC, ∏ GC are the ultra-filtration pressure, glomerular capillary 
hydrostatic pressure, hydrostatic pressure in Bowman’s capsule, oncotic pressure in 
Bowman’s capsule and oncotic pressure in glomerular capillary, respectively.  ∏ BC is 
mostly set to be zero due to virtual exclusion of proteins in the glomerular filtrate 
(Sherwood, 2006).  
      The ultra-filtration pressure is higher at the afferent end of glomerular capillary; it is 
about 12 mmHg and drops to zero at the efferent end of glomerular capillary as the 
blood transverses the length of glomerular capillary. This drop is attributed to the slight 
decrease in hydrostatic pressure due to resistance to flow caused by glomerular capillary 
and to the increase of intra-glomerular capillary oncotic pressure that result from the 
filtration of the protein free plasma, a factor that offsets the hydrostatic pressure and 
drops the ultra-filtration pressure fall to zero (Renkin and Robinson, 1974).  
     Kidney has a system of glomerular filtration auto-regulation which relies on 
regulation of the caliber and resistance of both the afferent and efferent arterioles, in 
such a way that the intra-glomerular capillary hydrostatic pressure is balanced 
 Eq. 1.1 
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according to the requirement (Christensen, et al., 2003). Normally, the caliber of 
afferent arteriole is bigger than that of efferent, a disproportionality that elevates intra-
glomerular hydrostatic pressure and increases vascularity of the glomerular bed 
(Sherwood, 2006).  
     Auto regulation mechanism is controlled by renal sympathetic nerve fiber and a 
series of systemic and local autacoids as angiotensin II, catecholamines, prostaglandins, 
thromboxans, adenosine, dopamine, nitric oxide (NO.), endotheline and ANP (Anti-
natriutic peptide). Angiotensin II, catecholamines, thromboxans, adenosine and 
endotheline act as afferent and efferent arterioles vasonstrictors leading to reduction of 
glomerular filtration rate while the rest have apposite function afferent and efferent 
arterioles. Auto regulation of glomerular filtration is accomplished by one of the two 
mechanisms; the myogenic where vasoconstriction incurs as a response to any stretch or 
the tubulo-glomerular feedback  mechanism, in which, the increase in sodium delivered 
to DCT triggers macula densa to activate the juxta-glomerular apparatus to release 
some autacoids as angiotensin II and adenosine which induce afferent arterioles 
vasoconstriction (Salman, et al., 1999; Vallon, 2003; Christensen, et al., 2003).  
       Renal tubular function is associated with the re-absorptive and secretory job of the 
ductile system that starts from the beginning of PCT and ends up in ducti of Billini 
(Thies, 1995).  
   PCT absorbs about 67% of electrolytes and water and almost all filtered glucose and 
amino acids. Sodium ion plays an important role in PCT’s function, since most of the 
sym-porters and anti-porters require sodium for proper functioning. Sodium re-
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absorption creates the required osmotic gradient for water re-absorption. Mechanism of 
sodium re-absorption in the early segment is different from that in the late segment. In 
the early segment, it is coupled with bicarbonate, phosphate and a number of organic 
molecules, such as; glucose, amino acids and lactate while it is coupled with chloride in 
the late segment. It is so avid that these solutes are almost completely cleared from 
tubular fluids in this segment leading to a great change in tubular fluid composition 
between the first and second halves. Most of the water soluble electrolytes can follow 
para-cellular route down their electrochemical gradient potential by a process called 
solvent drag. PCT cells can excrete both organic cations and anions through specific 
symporters and antiporters present on both the apical and basolateral membrane (Beck, 
et al., 1973; Neuman and Rector, 1976).  
    Tubular fluid leaves PCT towards loop of Henle where the counter current 
multiplication mechanism takes place in cooperation with vasa recta renis. This 
mechanism aims to increase osmolality of the renal interstitium at the deep inner 
medullary portion; an action that facilitates reabsorption of water from the medullary 
CT toward renal interstitium by the aid of ADH (anti diuretic hormone). Unlike the 
descending limb, thick ascending limb of loop of Henle is impermeable to water and 
permeable to ions. Its apical membrane is endowed with lots of frusemide sensitive 
Na+-K+-Cl- symporters which can actively extrude these ions from the tubular fluid. 
Like other tubular epithelia, basolateral membrane is endowed with lots of Na+-K+ 
ATPase pump mechanism which extrude Na+ toward the interstitium. The reabsorbed 
K+ can be recycled again to tubular fluid and translocated into the DCT. 
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     Accumulation of sodium in the interstitium elevates the interstitial osmolality and 
makes water to transfer from descending limb of the loop of Henle into the interstitium 
according to the osmolar gradient. Repetition of this process leads to a high osmotic 
pressure at the tip of the loop. Vasa recta renis acts to wash the reabsorbed fluid into the 
deep intra-medullary interstitium towards the cortical region (Layton and Weinstein, 
2002).  
       DCT is the site where Na+ is reabsorbed by the aid of Na+-Cl- co-transporters in the 
apical membrane and Na+-K+ ATPase pump in the basolateral membrane of the lining 
epithelium. Accordingly other electrolytes are re-absorbed by solvent drag mechanism 
along with reabsorbed water through the para-cellular shunt. Inside the CT ducti system 
urine volume and electrolyte composition are regulated. The system is rich in two types 
of cells; principle and intercalated cells. Principle cells are responsible for sodium re-
absorption in replacement of potassium ion. It is facilitated by basolateral Na+-K+ 
ATPase pump, apical membrane Na+ and K+ channels and the electrochemical gradient 
that push potassium to CT lumen. Intercalated cells are found mainly in the medullary 
region. They transfer some K+ and reabsorbed water in response to ADH  from the 
medullary CT toward renal interstitium (Thies, 1995). 
 
1.2 Aminoglycosides induced nephrotoxicity  
1.2.1 Aminoglycosides  
     Aminoglycosides are a group of structurally complicated antimicrobial compounds, 
composed of modified amino-sugar moieties linked by O-glycosidic linkage. They are 
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extracted from some species of Streptomyces bacteria or Micromonospora fungi and 
chemically modified for a stronger antimicrobial activity or to enervate its toxicity 
(Mitsuhashi, 1975). Their antimicrobial action is attributed to their ability to indispose 
bacterial protein synthesis and dismount the cell wall integrity (Lutwyche, et al., 1998). 
Toxicity of aminoglycosides is demarcated by being an oculo-, vestibulo-, cochlear and 
nephrotoxicity due to the specific cellular uptake mechanisms that epithelia of these 
organs possess for molecules having a cationic nature like aminoglycosides (Arya, 
2007; Mingut-Leclerq, et al., 1999). Leading to some notorious clinical signs and 
symptoms, such as oscillopsia (bouncing vision), blurred vision, tinnitus, vertigo, 
difficulty in balance, mental fogginess, short term memory lapse, tiredness and change 
in urine volume (Kelly, 2006). Hairy cells of vestibulocochlear apparatus in the middle 
ear, the oculo-retinal cells, the lining epithelium of renal proximal convoluted tubules, 
the neuromuscular junctions and the renal glomerular basement membrane of renal 
glomeruli are the main targets of aminoglycosides (Arya, 2007; Mingut-Leclerq, et al., 
1999).  
 
1. 2.2 Aminoglycosides induced nephrotoxicity   
     Aminoglycosides induced nephrotoxicity is a multi-step process, characterized by 
prominent changes in renal glomeruli and PCT (Rougier, et al., 2003).   
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1.2.2.1 Aminoglycosides induced tubular injury     
      It commences with the uptake of aminoglycosides by the simple cuboidal epithelial 
cells of pars recti segment of PCT. Due to their cationic nature, aminoglycosides can 
easily bind to acid phosphates that incrust the brush border as a precursory step for their 
subsequent intracellular internalization. Then they bind to megalin (a trans-membrane 
protein that binds to polybasic compounds like aminoglycoside and internalize them 
into the cytosol. The selectivity of aminoglycosides induced toxicity on PCT 
epithelium, hairy cells of vestibulocochlear apparatus and retinal epithelia is attributed 
to the megaline on their surface) (Nagai, et al., 2001; Pruiska, et al., 1997; Kanig et al., 
2008). As soon as they access the cytosol, they are engulfed by endosomes which 
provide an endocytic membrane transport shunt from plasma membrane to lysosomes 
(Sandoval, et al., 1998) where the environment is more acidic (PH=5), rendering 
aminoglycosides to be more cationic and increase their potency to bind to lysosomal 
membrane acid phosphates (that constitute about 5-20% of the membrane), leading to a 
cellular change known as lysosomal phospholipidosis (Schank, et al., 1992). In this 
case, lysosomal phospholipase and sphingomylinase enzymes lose their ability to break 
down phospholipids molecules. This in turn leads to a conspicuous accumulation of 
myeloid bodies in the form of intracellular aggregations of phospholipids, cholesterol 
and proteins (Kacew, 1987). When the critical threshold of intralysosomal concentration 
of aminoglycoside is reached, It bursts out to the cytosol inducing destructive changes 
in mitochondria and both the apical and basolateral membranes (Guirgea-Marion, et al., 
1986; Giuliano, et al., 1987). Inside the mitochondria, aminoglycosides bind with iron 
to form a complex with Fe++ which initiates lipid peroxidation and affects membrane 
13 
 
integrity that in turn leads to damping of mitochondrial internal respiration and decrease 
in ATP synthesis (Msastrasinh, et al., 1982; Zorov, 2010). The passive effect of 
gentamicin on apical and basolateral membranes integrity is attributed to lipid 
peroxidation and inhibition of ATP dependent transport mechanisms (Blias, et al., 
1993).  
     Hydropic degeneration may inflict tubular cells due to a decrease in ATP that is 
required for the active Na+-K+ pump, leading to Na+ retention and accumulation of an 
equimolar amount of water inside the cytoplasm as cytoplasmic vacuoles (Solez, 1986). 
If the destructive action pursues, necrosis may inflict injury to the cells. It is 
characterized by loss of cellular outlines and nuclear changes (karyopyknosis, 
karyorrehix and karyolysis) (Turton and Hooson, 1998). Progression of these events is 
controlled by chemical structure of the aminoglycoside which affects the ability of the 
drug to bind into the negatively charged phospholipids that incrust the brush border 
(Malis, 1984) and mode of the drug administration, as dosing and time interval 
(nephrotoxicity pattern differs if the drug is given in low or high dose and if the drug is 
given once a day, multiple doses or by continuous infusion). The single dosing system 
is less nephrotoxic as compared with the multiple dosing systems, as it creates just one 
peak of the drug plasma level while the multiple dosing systems create more (Reiner, 
1987). This is due to the nature of the cellular uptake of aminoglycosides which is a 
saturable process such that a finite quantity of drug transposes into the intracellular 
compartment after surpassing a certain critical threshold (Giuliano, et al., 1986).   
     There are many approaches that have been proposed to halt aminoglycosides induced 
nephrotoxicity. One of the approaches proposed using agents that make a complex with 
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aminoglycosides extracellularly or compete with the aminoglycosides at the binding 
sites. (For example; the series of polyaspartic acid derived compounds, like 
daptomycin) (Williams, 1985). Changing the mode of drug administration is another 
way to ameliorate the nephrotoxic effect of gentamicin (by switching the patient into 
the single dosing system, as mentioned above) (Reiner, et al., 1978).  
     Recently a series of aminoglycosides with a modified structure have been evolved. 
They have lower ability to bind to brush border or lysosomal phospholipids, e.g. 
amikacin, arbekacin and isepamicin (Carlier, et al., 1983). Another approach proposed 
is by using antioxidants and iron chelators. They intervene with the cascade sequential 
processes associated with intracellular aminoglycosides induced lipid peroxidation 
(Walker , et al., 1987).  
. 
 Figure 1.2:- The structure of kanamycin (The standard chemical structure of 
aminoglycoside molecule. IUPAC name (2-(aminomethyl)- 6-[4,6-diamino-3- [4-
amino-3,5-dihydroxy-6-(hydroxymethyl) tetrahydropyran-2-yl]oxy- 2-hydroxy- 
cyclohexoxy]- tetrahydropyran- 3,4,5-triol). Adapted from 
http://chemistry.about.com/od/factsstruc -tures/ig/Chemical-Structures 
K/Kanamycin.htm). 
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1.2.2 Gentamicin as an example of nephrotoxic aminoglycoside 
     Gentamicin is an aminoglycoside with methyl-N-substitution. Its chemical formula 
is C21H43N5O7  and its g.mwt is 488 gm/mole. It is a water soluble crystalline white to 
yellow colored powder. It is obtained from Micromonospora species; a genus of gram 
positive bacteria, disseminated widely in nature. It has a broad spectrum of bactericidal 
action against an array of gram negative bacteria, such as pseudomonas, niesseria, 
legionella and various coliform bacteria (Mitsuhashi, 1975). Gentamicin is more toxic 
as compared to other aminoglycosides due to its stronger ability to bind into acid 
phosphates (the targets of aminoglycosides-induced toxicity). This deterrent 
characteristic makes physicians more cautious while prescribing it (Carlier, 1980).  
      Bioavailability of gentamicin after oral administration is very poor while it is higher 
if it is given parenterally. Its hydrophilicity and molecular size allows it to permeate 
easily through the capillary endothelium (Segal, et al., 1988). Its Vd (volume of 
distribution) is affected by changes in total volume of extra-cellular fluids. In edema, 
the concentration decreases due to the increase in VD while in dehydration, the 
concentration goes up (Kelman, et al., 1984). Its binding to plasma proteins is weak and 
reaches 10-30%. Gentamicin is eliminated primarily by kidneys. Gentamicin has a very 
short half life which is higher in infancy as compared to higher ages. This difference 
may be due to the difference of GFR and renal function with different age groups. 
(Vozeh, et al., 1979).  
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Figure 1.3:- Chemical structure of gentamicin. IUPAC name (diamino-3  
3-amino-6-1-(methylamino)ethyl]oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-5-methyl-
4-(methylamino)oxane-3,5-diol) (Mitsuhashi, 1975).  
       
     Therapeutic plasma concentration of gentamicin ranges from 2 to 12 µgm/ml. The 
minimum value represents the MIC (minimum inhibitory concentration) for bacteria 
while the highest one represents the critical threshold concentration. So as an antibiotic, 
it should be given in a dose that keeps the concentration between the two thresholds. In 
human, the therapeutic dose that maintains it within the abovementioned range is about 
4-7 mg/kg(B.W)/ day. Higher doses make the concentration higher than this range. In 
rats, the dose that maintains the concentration within the therapeutic level is about 10-
20 mg/Kg (B.W)/day. It is documented that nephrotoxicity in rats is induced at a dose 
exceeding 40 mg/ Kg (B.W)/day. In one study, after a single injection of 100 mg/kg 
gentamicin, the plasma level rose to168 µgm/ml (Stahlmann, et al., 1988).   
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1.3 Oxidative stress 
     Oxidative stress is evolved due to constant interaction of the body with oxygen 
during intracellular respiration resulting in unleashing of highly reactive molecules, 
known as free radicals. Cells are endowed with a redox system, responsible for 
mopping free radicals out by scavenging them (Sies, 1991). Free radical molecules 
hareve an atom with an unpaired electron in its outer shell, making them highly reactive 
species with a tendency to attack various biomolecules. It is formed due to heterophilic 
breakdown of covalent bonds during cellular metabolism (Nonhebel and Walton, 1974). 
     When the free radical is formed, a series of chain propagation reactions are triggered. 
They are called electron transport chain (ETC). In these reactions, each newly formed 
radical looks to return into its original state by stealing another electron with antiparallel 
spin from the surrounding environment. This in turns evolves more new radicals. ETC 
mostly happens inside the mitochondria where oxygen is used to generate energy and 
acts as an electron acceptor (Gropper, et al, 2008).  
     Free radicals target double bonds in poly unsaturated free fatty acids (PUFFAs) 
resulting in a heterophilic breakdown of C-H bonds attached to the double bonds. 
PUFFAs contain one or more methelene groups between the double bonds. They are 
highly reactive to oxidizing agents and can easily lose their hydrogen after forming 
carbon centered radicals (Gropper, et al, 2008). In an effort to stabilize it, molecular 
rearrangement occurs which converts the molecule into more stable form called 
conjugated diene (CD). CDs tend to react with other oxygen molecule to form 
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peroxyradicals which look to attack other PUFFAs' double bonds, leading to continuous 
repetition of this process (radical chain propagation reaction) (Gropper, et al, 2008).  
     After the formation of peroxy radicals, either they are reduced to hydroperoxides 
which are relatively more stable or they suffer sequence of reactions associated with 
intramolecular cyclization, leading to generation of a broad range of products (Mittler, 
2002) (Figure 1.4). 
  
 
Figure 1.4:-Lipid peroxides fate pathways (adapted from Mittler, 2002). 
       Final products of lipid peroxidation are either aldehydes, like formaldehyde, 
acetyladehyde, acrolien, malonyldialdehyde (MDA),4-hydroxyhexenal (4-HHE) and 4-
hydroxnonenal (4-HNE), oxaloaldehydes such as glyoxal and methyl glyoxal, ketones 
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such as; acetone and butanone and some alkanes such as; hexane, cyclohexane and 
heptanes (Mittler, 2002). MDA is the most convenient biomarker of lipid peroxidation 
among them because of its plain reaction with thiobarbituric acid (TBA) to form TBA-
MDA adduct that is easy to be detected calorimetrically (Akhgari, et al., 2003). 
Recently, F2- isoprostane is used as a marker as well (Tianying, et al., 2004).  Aldehyde 
products of lipid peroxidation are relatively less harmful than the free radicals, although 
they have a tendency to form Schiff bases with lysine, histidine and cysteine residues of 
proteins and nitrogen bases of DNA backbone leading to conformational changes of the 
proteins along with loss of their function and some genotoxic and mutagenic effects due 
to DNA binding (Cederbaum, 2001; Cohen , et al., 1984; Kharbanda , et al., 2002). 
 
1.3.1 Types of free radicals 
     Free radicals are either reactive oxygen species (ROS) or reactive nitrogen species 
(RNS) depending on whether oxygen or nitrogen is centered in (Nonhebel and Waton, 
1974).   
 
 1.3.1.1 Reactive oxygen species 
     Reactive oxygen species (ROS) include; superoxide anion (•O2-), hydrogen peroxide 
(H2O2), hydroxyl radical (•OH), alkoxy radicals (RO•), peroxy radicals (ROO•) and 
hypochlorous acid (HOCl). Oxygen has a tendency to be reduced in sequential 
univalent processes releasing intermediates such as •O2-, H2O2 and •OH (Uday, 1999).   
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    Leakage of electrons during ETC reaction in mitochondria results in oxygen 
reduction. ETC reaction accompanies steps associated with oxidation of hydroxyacids 
icas those in citric acid cycle, amino acids or fatty acids. Nicotinamide adenine 
dinucleotide (NADPH) acts as a source of reducing equivalents in these reactions. It 
donates electrons to cytochrom P450 via flavoproteins. Cytochrom P450 reduces 
oxygen to water without the formation of •O2-. Any disturbance in mitochondrial 
function reaction leads to leakage of electrons and release of •O2-.  
     As soon as •O2- is released, it is dismutated spontaneously or by the aid of super 
oxide dismutase enzyme (SOD) forming H2O2. •O2- is rather inactive and has very poor 
penetration through plasma membrane while hydrogen peroxide is more active and 
especially ferrous and cuprous ions induce release of •OH by a reaction called Fenton 
reaction ( Uday, et al., 1999). These metal ions are not found freely and mostly are 
bound to a tissue protein called metalloprotein. They are released during cellular 
degeneration and tigger Fenton reaction (Aruoma, 1989). •OH is extremely active and 
due to its low diffusion capacity, it damages any molecule in its vicinity (Uday, et al., 
1999).  
     Inside the body, there are two defensive mechanisms to mop ROS out; the primary 
one which is represented by antioxidant enzymes and the secondary one which is 
represented by the antioxidants which exist in dietary supplements. SOD, catalase and 
glutathione system represent the enzymatic system that mop out ROS. SOD is a 
metalloprotein. It contains copper and zinc as cofactor ions. It dismutates •O2- to H2O2. 
Catalase enzyme is present in peroxosomes. It is a hem-protein that catalyzes 
conversion of H2O2 to water and oxygen.  
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 Figure 1.6:- Glutathion-ascorbate cycle to detoxify H2O2. Apx:-Ascorbate peroxidase 
enzyme, MDA: - Monohydroascorbate, MDAR: - Monohydroascorbate reductase, 
GPx:- glutathione peroxidase enzyme, Gr:- glutathione reductase enzyme, GSH:-
reduced form of glutathione, GSSG:-Oxidized form of glutathione (May, et al., 1996).  
      
1.3.1.2 Reactive nitrogen species RNS 
     Nitric oxide (NO.) and peroxynitrate (ONOO) are the RNS forms of free radicals. 
NO. is produced extensively by endothelial cells as a short lived paracrine physiological 
transmitter that mediates vascular smooth muscles dilation and inhibition of platelets 
aggregation through activation of cGMP and decreasing intracytosolic calcium 
concentration. Furthermore, it inhibits endothelial function by acting as a gene 
modulator preventing the expression of surface adhesion molecules as VCAM-1 and 
ICAM-1which are required for leukocyte adhesion and development of atherosclerotic 
events (Van der, et al., 1999; Walker, et al., 2001).  
     During oxidative stress, NO. reacts with superoxide radical generating peroxynitrate 
(ONOO.). Peroxynitrate is a strong free radical. It induces free radical chain propagation 
reaction and nitrosation of tyrosine residues of proteins and nitrogen bases of DNA 
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 leading to cellular dysfunction and mutation (Van der, et al., 1999; Walker, et al., 
2001). The human body fends this pathway through triggering nitrate-nitrite-nitric oxide 
pathway. When the amount of NO. exceeds the threshold, NO. is oxidized to nitrite 
(NO2-) and then to nitrate (NO3-) by aid of multicopper oxidase system, cerruloplasmin 
and oxyhaemoglobin which converts to methaemoglobin (Van der, et al., 1999; Walker, 
et al., 2001).  
     Conversion of NO. to NO2- and NO3- is a bidirectional process which occurs either 
spontaneously after disturbance of the chemical balance or triggered by enzymes. On 
the other hand, NO.  could be evolved from NO2- and NO3- by aid of nitrate reductase 
enzyme produced by gastrointestinal commensal bacteria (Lundberg, et al., 2008). 
Regulation of protein function through nitrosylating its thiol groups by NO. is another 
mechanism that the body is endowed to discard excessive NO. radical (Walker, et al., 
2001). 
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ic oxide inside the body (Walker, et al., 2001). 
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1.3.2 Dietary antioxidants 
     Diet provides plenty of biochemical compounds able to counteract oxidative stress 
and enforce the defensive processes against free radicals generation. These compounds 
are either vitamin products , as vitamin A, vitamin E and vitamin C which are found in 
animal and plants products such as some carotenoid derivatives (zeaxanthine, lycopene 
and lutein) and polyphenols (Shahidi, 1997).  
     Polyphenols are water soluble chemical compounds that bear more than one phenolic 
groups. Phytochemical polyphenols are classified into:-tannins, flavonoids and 
phenylpropanoids (Shahidi, 1997).  
     Palm oil leaf extract used in our study, contains polyphenols with catechin and 
ferrulic acid constituting the majority. Catechin is a tricyclic flavonoid derivative. It 
possesses an antioxidant activity due to the presence of phenolic groups attached to 
benzene ring (Chumbalov, et al., 1995). Ferrulic acid is a phenylpropanoid derivative, 
found in plant cell wall as a covalent side chain attached to arabinoxylan and cellulose 
of the cell wall. Inside the plant, it serves to crosslink lignine to polysaccharides adding 
some rigidity to the cell wall. Previous studies reveal that after ingestion, ferrulic acid is 
absorbed in gastrointestinal tract after cleavage of its linkage with lignines by pancreatic 
acids (Pan, et al., 1999). It has better bioavailability in plasma as compared to other 
polyphenols (Scheliner, 1968). Ferrulic acid has a unique antioxidant power due to the 
presence of carboxyl group in its structure which acts as a free fatty acid anchor in 
membranous structures resulting in higher anti lipid peroxidation effect (figure 1.8) 
(Kanski, et al., 2002).   
